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ABSTRACT 
Objective: To develop a simple, selective and rapid reversed phase high performance liquid chromatographic (HPLC) method for the analysis of 
cefixime and moxifloxacin in combined pharmaceutical dosage form as per ICH guidelines. 
Methods: The separation was achieved from C18 column at 350
Results: The calibration curve was linear over the concentration range of 20-120 μg/ml (r
C with a mobile phase consisting of methanol: 0.05M heptane sulfonic acid sodium 
salt,0.5 ml THF and 0.5 ml TEA [75: 25 v/v]. pH-3.8 was adjusted with ortho phosphoric acid at a flow rate of 0.4 ml/min and the retention time was 
about 6.08 minutes for cefixime and 6.94 minutes for moxifloxacin. The method was selective to cefixime and moxifloxacin able to resolve the drug 
peak from formulation excipients. 
2
Conclusion: A novel, simple, selective and rapid reversed phase high performance liquid chromatographic (HPLC) method was developed for the 
analysis of cefixime and moxifloxacin in tablets. Hence,the method can be used for the routine analysis in various pharmaceutical industries. 
 = 0.999) for both drugs. The proposed method was 
found to be accurate and precise and linear within the desired range. The limit of detection (LOD) and limit of quantitation (LOQ)were calculated 
statically. Recoveries do not differ significantly from 100% which show there was no interference from the common excipient used in tablet 
formulation indicating accuracy and reliability of the method. The method was validated as per ICH guidelines and found to be accurate, precise and 
rugged. The method was validated in terms of linearity, accuracy, precision, specificity, LOD and LOQ.  
Keywords: Simultaneous estimation, Cefixime, Moxifloxacin, RP- HPLC, Validation, Tetrahydrofuran (THF), Triethylamine(TEA). 
 
INTRODUCTION 
Cefixime (CEF) (Figure 1) is official in United State 
Pharmacopoeia[1],British Pharmacopoeia[2]. Cefixime is (6R,7R)-7-
{[2-(2-amino-1,3-thiazol-4-yl)-2- (carboxy methoxyimino) 
acetyl]amino} -3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0] oct-2-ene-
2-carboxylic acid. It is anantibacterial agent and used to treat 
urinary tract infections,otitis[3] bronchitis, pneumonia,Prostatitis, 
syphilis and infections of reproductive organs[4, 5, 6]. Moxifloxacin 
is official in British Pharmacopoeia[7]. Moxifloxacin(MOX)(Figure 
2)is a 1-Cyclopropyl-6-fluoro-8-methoxy-7-[(4aS, 7aS) -octahydro-
6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-1,4-dihydroquinoline-3 
carboxylic acid hydrochloride[7]. It is afourth generation 
fluoroquinolone broad spectrum antibiotic agent used in 
conjunctivitis[8]. Literature survey reveals that number of methods 
such as spectrophotometric[4, 9,10], HPLC[11, 12], 
HPTLC[13],colorimetric[14], spectroflurometric[15]are reported for 
the estimation of CEF from its formulation or biological fluids. 
Similarly number of methods such as spectrophotometric[16, 17] 
spectrofluorometric[18], RP-HPLC[19, 20], voltametric[21] were 



















Fig. 1: Structure of cefixime 
 
This paper is in continuation with our work [24-29], where we 
studied chromatographic method for single or multicomponent 
drugs. So, present study was aimed to develop andvalidate RP-HPLC 
method forsimultaneous estimation of cefixime andmoxifloxacin 
from combined dosage form which would be simple, cost effective 
and easily adopted by small laboratories. The proposed method was 












Fig. 2: Structure of moxifloxacin 
 
MATERIALS AND METHODS 
Apparatus 
200Elmer seriessystem of PerkinchromatographicThe liquid
(Mumbai, variablepump,gradientquaternarycontainingIndia)
wavelength programmable PDA detector, and auto sampler with 10 
μL fixed loop was used. For analysis a hypersil C18
Reagents and materials 
 column with 250 
×4.6 mm i. d. and 5 μm particle sizes were used as stationary phase. 
Working standard of cefixime was pursued as a gift sample from FDC 
Pharma Ltd., (Mumbai, India) and moxifloxacinwas pursued as a gift 
sample from Dr. Reddy’s lab Ltd., (Hydrabad, India). All chemicals 
and solvents of HPLC grade and were purchased from Rankem Ltd., 
(Mumbai, India). Marketed formulation of tablet containing cefixime 
and moxifloxacin was used as the sample which was purchased from 
the local market. 
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Preparation of mobile phase 
The mobile phase was prepared by mixing methanol: 0.05M 
heptanes sulfonic acid sodium salt, 0.5 ml THF and 0.5 ml TEA in 
75:25 v/v ratio and pH was adjusted to 3.8 with orthophosphoric 
acid. The whole mobile phase was sonicated for 15 min and then 
filtered through 0.45 μm membrane filter paper.  
Standard stock solution of Cefixime and Moxifloxacin (400 
μg/ml)  
40 mg of standard drugs cefixime (CEF) and moxifloxacin (MOX) was 
dissolved separately in 100 ml of the mobile phase. Then the 
volumes were made up to the mark with mobile phase to get 400 
μg/ml of standard stock solutions and sonicated for 10 minute. 
These stock solutions were filtered through 0.45 μm membrane 
filter paper. For the preparation of working standard, suitable 
aliquots of stock solutions were pipette out and volumes were made 
up to the mark with mobile phase. 
Chromatographic conditions 
The hypersil C18 column (5 𝜇𝜇 × 250 mm × 4.6 mm) equilibrated with 
mobile phase methanol: 0.05 M heptanes sulfonic acid sodium salt, 
0.5 ml THF and 0.5 ml TEA (75:25 v/v), pH 3.8 adjusted with 
orthophosphoric acid was used. The flow rate was maintained at 0.4 
mL/min. Eluents were monitored with PDA detector at 284 
nm,temperature was maintained at 35 o
Preparation of calibration curve of cefixime and moxifloxacin 
C and the injection volume 
was 10 𝜇𝜇L. Total run time was kept for 10 min. 
Appropriate aliquots of the standard stock solution of CEF and MOX 
were pippetted out and transferred to a series of 10 ml volumetric 
flasks to obtain a concentration range of 20-120 μg/ml for both the 
drugs. Triplicate dilutions of each concentration were prepared 
separately and 10 μl of each concentration of the drug were injected 
into the HPLC system two times separately.  
The chromatograms were recorded under the same 
chromatographic conditions as described above. Peak areas were 
determined and a standard calibration curve of peak area against 
concentration was plotted. The individual chromatograms of 
standard CEF and MOX are shown in (Fig. 3, 4). Observation for 
calibration curve are shown in table 1. 
  
 
Fig. 3: Chromatogram of CEF 
 
 
Fig. 4: Chromatogram of MOX 
 
Analysis of the marketed formulation 
Twenty tablets were weighed accurately and triturated to produce 
fine powder. A quantity equivalent to 400 mg of CEF and 400 mg of 
MOX was weighed and transferred to 100 ml volumetric flask and 
volume was made up to 100 ml with mobile phase. The contents 
were sonicated for 10 min and filtered through 0.45 μm membrane 
filter paper. 
 
Table 1: Observation for standard calibration curve of CEF & MOX 






1 20 1106091 229578 
2 40 2155165 442897 
3 60 3226470 669104 
4 80 4324397 907328 
5 100 5422408 1114156 
6 120 6411023 1344018 
 
 
Fig. 5: Calibration curve for CEF 
 
 
Fig. 6: Calibration curve for MOX 
 
By appropriate dilution of this stock solution with mobile phase, 
further sample solutions were prepared within the concentration 
range for two drugs. A 10 μl volume of each sample solution was 
injected into HPLC system for six times under the chromatographic 
condition as stated above. Result of analysis of the marketed 
formulation presented in Table 2. 
 
 
Fig. 7: Chromatogram for mixture of CEF and MOX 
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The calibration curves were found to be linear over concentration 
range 20-120 μg/ml for both CEF and MOX. The results of linearity 
studies are given in Table 3.  
Recovery study 
Recovery study was carried out at three levels i. e. 80, 100 and 120 
% of the label claim of the tablet formulation as per ICH guidelines. 
Results of recovery study are given in Table 5. 
Precision  
Precision of the method was verified by using stock solutions in 
concentration containing 80 µg/ml of CEF and MOX. System 
repeatability was done by repeating the assay three times of six 
replicate dilutions of the same concentration after every two hours 
on the same day for intraday precision. Interday precision was 
carried out by performing the assay of six sample sets after 24 hrs 
and 48 hrs. The results of precision study are given in Table 6. 
Robustness 
To evaluate the robustness, the developed method was subjected to 
small deliberate variations in the optimized method parameters like 
the variation of flow rate ±0.2 ml/min, temperature of column ±20
Limit of detection and limit of quantitation (LOD and LOQ) 
C, 
ratio of mobile phase ±2%, pH of mobile phase±0.2. The method was 
found to be robust as the slight deliberate variations in parameters 
did not lead to changes in retention times of peak of interest. While 
evaluating the robustness data, it was observed that 
systemsuitability parameters (e. g. tailing factor, plate counts, 
resolutions etc.) were found to be within the specified limits under 
those deliberately varied conditions, which ensures that the validity of 
the analytical procedure was maintained whenever used. The result of 
robustness study is summarized below in Table 7, 8, 9, 10. 
The sensitivity of measurement for CEF and MOX was estimated in 
terms of the limit of quantitation (LOQ). The smallest amounts 
detected under the chromatographic conditions used were 
estimated in terms of the limit of detection (LOD). LOQ and LOD 







Where σ is the standard deviation of the peak areas of the drugs, 
taken as a measure of noise, and S is the slope of the corresponding 
calibration curve.  
RESULTS AND DISCUSSION 
The proposed RP-HPLC method, allows a rapid and accurate 
quantitation of cefixime and moxifloxacin in combined pharmaceutical 
dosage form as per ICH guidelines. The chromatograms of standard CEF 
and MOX are shown in (Figure 3, 4). The standard calibration curves 
(Figure 5, 6) were plotted separately as peak area against the respective 
concentration of CEF and MOX. The linearity of both drugs was found in 
acceptable range. The accuracy of the proposed method was determined 
by recovery studies (Table 5), indicating an agreement between the true 
value and found value. Precision was calculated as interday and intraday 
variation of given drugs. Percent relative standard deviations for 
estimation of cefixime and moxifloxacin under intraday and interday 
variations were found to be less than 2 (Table 6). For robustness 
studies in all deliberately varied conditions percent relative 
standard deviations were found to be less than 2 % (Table 7 - 10). 
Table 2: Results of marketed tablet formulation 
Formulation * SD Mean Recovery %RSD 
CEF 99.98 0.320 0.323 
MOX 99.92 0.050 0.0501 
*Denotes average of 6 determinations 
 
Table 3: Linear regression data for calibration curve of CEF and MOX 
Drug Linearity range (μg/ml) r² Slope Intercept 
CEF 20-120 0.999 53634 17051 
MOX 20-120 0.999 11189 1122 
 
Table 4: Results of LOD & LOQ 
Parameters CEF MOX 
LOD (µg/ml) 0.00061 0.00294 
LOQ (µg/ml) 0.002019 0.009760 
 
Table 5: Results of Recovery Study 
Level of  
recovery 
% Recovery* SD % RSD 
CEF MOX CEF MOX CEF MOX 
80% 99.87 99.87 0.0467 0.0383 0.0468 0.03835 
100% 99.96 99.94 0.0608 0.0526 0.0608 0.05263 
120% 99.95 99.89 0.0079 0.0375 0.0079 0.03754 
 
Table 6: Results of Precision 
Formulation Parameter Intra-day precision*  Inter-day precision* 
 
CEF 
% Mean 99.82 99.87 
SD 0.39 0.35 
%RSD 0.3907 0.3504 
 
MOX 
% Mean 99.89 99.84 
SD 0.058 0.059 
%RSD 0.0580 0.0590 
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Table 7: Flow Rate (ml/min) 
Flow Retention Time (min) Tailing Factor Peak Area % Content Found 
CEF MOX CEF MOX CEF MOX CEF MOX 
0.2 12.35 14.73 1.41 1.33 3520029 759106.2 99.98 99.93 
0.4 6.06 6.94 1.361 1.244 3520483 759626.5 99.99 100 
























Table 8: Column temperature 
Temp. Retantion Time Tailing Factor Peak Area % Content Found 
CEF MOX CEF MOX CEF MOX CEF MOX 
33 6.04 6.9 1.43 1.32 3518692 757273.5 99.94 99.69 
35 6.06 6.94 1.36 1.25 3498490 759697 99.37 100.00 




















Table 9: pH of mobile phase 
pH Retantion Time 
(min) 
Tailing Factor Peak Area % Content Found 
CEF MOX CEF MOX CEF MOX CEF MOX 
3.6 6.14 6.97 1.36 1.41 3500583 753646 99.43 99.21 
3.8 6.06 6.94 1.35 1.23 3528133 758829 100.21 99.89 
4 6.12 7.38 1.32 1.21 3501232 749989 99.45 98.73 
*Mean  


















Table 10: Ratio of mobile phase 
Ratio Retention Time (min) Tailing Factor Peak Area % Content Found 
CEF MOX CEF MOX CEF MOX CEF MOX 
27:73 6.12 7.47 1.4 1.43 3550302 752911.2 100.84 99.11 
25:75 6.06 6.94 1.35 1.23 3510483 759926.5 99.71 100.03 
23:77 6.06 7.09 1.32 1.19 3501884 750200.6 99.47 98.75 


















The objective of the work was to develop the simple, accurate, 
precise and sensitive HPLC method for the estimation of cefixime 
and moxifloxacin in bulk and multicomponent formulation. From the 
results obtained by all parameters, it is concluded that developed 
RP-HPLC method is suitable for the simultaneous estimation of 
cefixime and moxifloxacin in bulk and multicomponent formulation. 
The concentration of CEF and MOX in pharmaceutical dosage form 
could be satisfactorily determined using isocratic RP-HPLC system 
with PDA detector. This method has been found suitable for the 
routine analysis of pharmaceutical dosage forms in QC and R & D 
laboratories for products of similar type and composition. 
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